» Articles » PMID: 38891780

Rapid Determination of Kinetic Constants for Slow-Binding Inhibitors and Inactivators of Human Histone Deacetylase 8

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jun 19
PMID 38891780
Authors
Affiliations
Soon will be listed here.
Abstract

The kinetics and mechanism of drug binding to its target are critical to pharmacological efficacy. A high throughput (HTS) screen often results in hundreds of hits, of which usually only simple IC values are determined during reconfirmation. However, kinetic parameters such as residence time for reversible inhibitors and the / ratio, which is the critical measure for evaluating covalent inactivators, are early predictive measures to assess the chances of success of the hits in the clinic. Using the promising cancer target human histone deacetylase 8 as an example, we present a robust method that calculates concentration-dependent apparent rate constants for the inhibition or inactivation of HDAC8 from dose-response curves recorded after different pre-incubation times. With these data, hit compounds can be classified according to their mechanism of action, and the relevant kinetic parameters can be calculated in a highly parallel fashion. HDAC8 inhibitors with known modes of action were correctly assigned to their mechanism, and the binding mechanisms of some hits from an internal HDAC8 screening campaign were newly determined. The oxonitriles SVE04 and SVE27 were classified as fast reversible HDAC8 inhibitors with moderate time-constant IC values of 4.2 and 2.6 µM, respectively. The hit compound TJ-19-24 and SAH03 behave like slow two-step inactivators or reversible inhibitors, with a very low reverse isomerization rate.

Citing Articles

Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?.

Raouf Y, Moreno-Yruela C JACS Au. 2024; 4(11):4148-4161.

PMID: 39610753 PMC: 11600154. DOI: 10.1021/jacsau.4c00828.

References
1.
Copeland R, Pompliano D, Meek T . Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006; 5(9):730-9. DOI: 10.1038/nrd2082. View

2.
Burli R, Luckhurst C, Aziz O, Matthews K, Yates D, Lyons K . Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. J Med Chem. 2013; 56(24):9934-54. DOI: 10.1021/jm4011884. View

3.
Copeland R . Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal. 2005; 46:1-265. View

4.
Schweipert M, Jansch N, Sugiarto W, Meyer-Almes F . Kinetically selective and potent inhibitors of HDAC8. Biol Chem. 2018; 400(6):733-743. DOI: 10.1515/hsz-2018-0363. View

5.
Ranjbarvaziri S, Zeng A, Wu I, Greer-Short A, Farshidfar F, Budan A . Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice. Nat Commun. 2024; 15(1):1352. PMC: 10897156. DOI: 10.1038/s41467-024-45440-7. View